197 related articles for article (PubMed ID: 34349054)
21. Lineage switch of acute myeloid leukemia to T-Cell acute lymphoblastic leukemia - A unique case report.
Jamil SF; Sharma U; Singh C; Bansal S
Indian J Pathol Microbiol; 2023; 66(1):191-195. PubMed ID: 36656240
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
23. Lineage Switch Between B-Lymphoblastic Leukemia and Acute Myeloid Leukemia Intermediated by "Occult" Myelodysplastic Neoplasm: Two Cases of Adult Patients With Evidence of Genomic Instability and Clonal Selection by Chemotherapy.
Wu B; Jug R; Luedke C; Su P; Rehder C; McCall C; Lagoo AS; Wang E
Am J Clin Pathol; 2017 Aug; 148(2):136-147. PubMed ID: 28898985
[TBL] [Abstract][Full Text] [Related]
24. Lineage switch with t(6;11)(q27;q23) from T-cell lymphoblastic lymphoma to acute monoblastic leukemia at relapse.
Higuchi Y; Tokunaga K; Watanabe Y; Kawakita T; Harada N; Yamaguchi S; Nosaka K; Mitsuya H; Asou N
Cancer Genet; 2016 Jun; 209(6):267-71. PubMed ID: 27268298
[TBL] [Abstract][Full Text] [Related]
25. Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Guolo F; Minetto P; Clavio M; Miglino M; Lemoli RM; Gobbi M
Biosci Trends; 2017 Mar; 11(1):110-114. PubMed ID: 28123146
[TBL] [Abstract][Full Text] [Related]
26. [Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia].
Qin T; Xu Z; Zhang Y; Lin Y; Ru K; Fang L; Zhang H; Pan L; Hu N; Qu S; Wang J; Xing R; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):94-9. PubMed ID: 27014976
[TBL] [Abstract][Full Text] [Related]
27. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia.
Shiomi I; Nakako S; Nakane T; Ogawa Y; Araki T; Fujitani Y; Yamamura R; Hino M; Nakamae H
Int J Hematol; 2024 Jan; 119(1):88-92. PubMed ID: 38010569
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
[TBL] [Abstract][Full Text] [Related]
31. [Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].
Qian SX; Li JY; Wu HX; Lu H; Qiu HX; Chen LJ; Lu RN; Xu W; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):209-13. PubMed ID: 19236781
[TBL] [Abstract][Full Text] [Related]
32. Molecular and phenotypic analysis of Philadelphia chromosome-positive bilineage leukemia: possibility of a lineage switch from T-lymphoid leukemic progenitor to myeloid cells.
Monma F; Nishii K; Ezuki S; Miyazaki T; Yamamori S; Usui E; Sugimoto Y; Lorenzo V F; Katayama N; Shiku H
Cancer Genet Cytogenet; 2006 Jan; 164(2):118-21. PubMed ID: 16434313
[TBL] [Abstract][Full Text] [Related]
33. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
[TBL] [Abstract][Full Text] [Related]
34. Importance of Acute Lymphoblastic Leukemia-type Therapy for Bilineal Acute Leukemia.
Nakagawa S; Okamoto Y; Kodama Y; Nishikawa T; Tanabe T; Kawano Y
J Pediatr Hematol Oncol; 2019 Aug; 41(6):504-506. PubMed ID: 30198961
[TBL] [Abstract][Full Text] [Related]
35. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Jabbour E
Leuk Lymphoma; 2018 Apr; 59(4):813-820. PubMed ID: 28718728
[TBL] [Abstract][Full Text] [Related]
36. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
37. Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature.
Huh JY; Chung S; Oh D; Kang MS; Eom HS; Cho EH; Han MH; Kong SY
Korean J Lab Med; 2010 Apr; 30(2):117-21. PubMed ID: 20445327
[TBL] [Abstract][Full Text] [Related]
38. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
[TBL] [Abstract][Full Text] [Related]
39. A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D; Boluda B; Martínez P; Bergua J; Rodríguez-Veiga R; Esteve J; Vives S; Serrano J; Vidriales B; Salamero O; Cordón L; Sempere A; Jiménez-Ubieto A; Prieto-Delgado J; Díaz-Beyá M; Garrido A; Benavente C; Pérez-Simón JA; Moscardó F; Sanz MA; Montesinos P;
Ann Hematol; 2018 May; 97(5):763-772. PubMed ID: 29392425
[TBL] [Abstract][Full Text] [Related]
40. FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children.
McCarthy AJ; Pitcher LA; Hann IM; Oakhill A
Med Pediatr Oncol; 1999 Jun; 32(6):411-5. PubMed ID: 10358698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
